ライフサイエンスコーパス: psychotropic medication

1 tment are most likely to receive concomitant psychotropic medication.

2 sychiatric facilities were given concomitant psychotropic medication.

3 ents, and patients who were not prescribed a psychotropic medication.

4 re not depressed, and none had ever received psychotropic medication.

5 nces were found in patients currently taking psychotropic medication.

6 present whether or not the participant takes psychotropic medication.

7 e the likelihood of off-label prescribing of psychotropic medication.

8 pression is associated with being prescribed psychotropic medication.

9 ic disorder, current depression, and current psychotropic medication.

10 n antipsychotic drug treatment with a second psychotropic medication.

11 None was taking psychotropic medication.

12 and increased public acceptance of effective psychotropic medications.

13 e course of 10 years to examine their use of psychotropic medications.

14 treatment for weight gain in patients taking psychotropic medications.

15 physicians and provided in conjunction with psychotropic medications.

16 actures based on mental disorders and use of psychotropic medications.

17 milar regions of the brain, or the effect of psychotropic medications.

18 articipants were weight-restored and free of psychotropic medications.

19 K3beta activity contributes to the action of psychotropic medications.

20 antidepressants, or other nonantidepressant psychotropic medications.

21 pulation or among control groups using other psychotropic medications.

22 Adjustments were made for other psychotropic medications.

23 ht also exhibit changes after treatment with psychotropic medications.

24 nstrated following administration of several psychotropic medications.

25 ation services, neurologic events, or use of psychotropic medications.

26 were not using any mental health services or psychotropic medications.

27 of individuals with dose increases in their psychotropic medications.

28 ied by a commensurate increase in the use of psychotropic medications.

29 ithout mental disorders and those not taking psychotropic medications.

30 tions, new prescriptions, or daily doses for psychotropic medications.

31 der (22.5% vs 5.8%; P = .005), and receiving psychotropic medications (18.0% vs 4.7%; P = .007), intr

32 s before the cancer death/index date, use of psychotropic medication 6 months before the cancer death

33 oms were more likely to have been prescribed psychotropic medication (adjusted odds ratio = 1.9; 95%,

34 total brain volume, age, gender, education, psychotropic medications, alcohol use, and race/ethnicit

35 e of the most commonly prescribed classes of psychotropic medications among US youths.

36 ehavior disorders as well as nonadherence to psychotropic medication and lower socioeconomic levels.

37 Use of psychotropic medication and presence of comorbid major d

38 both relative to patients not receiving any psychotropic medication and relative to their pretreatme

39 effect persisted after covarying for current psychotropic medication and severity of current depressi

40 ated the relative mortality, prescription of psychotropic medication and use of primary medical care

41 -SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically

42 riod of expansion in the number of available psychotropic medications and growth in managed behaviora

43 Before treatment, all subjects were free of psychotropic medications and had a score </=20 on the Ce

44 Maintenance psychotropic medications and supportive psychotherapy we

45 te the associations between major classes of psychotropic medications and violent reoffending.

46 human resources, rehabilitation facilities, psychotropic medication, and community mental health as

47 duration of inpatient admissions, the use of psychotropic medication, and self-report measures of dep

48 rimary care physicians prescribe concomitant psychotropic medication, and they show great variability

49 using mental health services (talk therapy, psychotropic medication, and/or a support group), most c

50 er involvement of physicians, greater use of psychotropic medications, and expanding availability of

51 12-month mental disorder had been prescribed psychotropic medications, and most had evidence of psych

52 otic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on i

53 ds with or without dispensed prescription of psychotropic medications (antipsychotics, antidepressant

54 Psychotropic medications are widely prescribed, but how

55 f comorbid major depressive disorder, use of psychotropic medications, assay used, and time of day bl

56 , most patients in these studies were taking psychotropic medications at the time of PPI testing, and

57 diagnosis of MDD, not currently treated with psychotropic medication, between ages of 18 and 65 (mean

58 scribes the prevalence and pattern of use of psychotropic medications by HIV-positive patients receiv

59 Abrupt discontinuation of long-term psychotropic medication can be followed by a high risk o

60 erformed to assess risk of fetal exposure by psychotropic medication class.

61 ecently diagnosed OCD who had never received psychotropic medication demonstrated no cognitive impair

62 sions to terminate a pregnancy if prescribed psychotropic medication during early pregnancy than if n

63 Given concerns about use of psychotropic medication during pregnancy, the authors re

64 otic symptoms (47.6%) had taken a prescribed psychotropic medication during the last month.

65 onth), 4.1% of whom had a prescription for a psychotropic medication during the study period.

66 Use of psychotropic medications during pregnancy is appropriate

67 U.S. prescriptions (156.9 million claims for psychotropic medications during the study period) and a

68 ng participants who did not voluntarily take psychotropic medication, even minor assaultiveness was a

69 Psychotropic medication exposure has been shown to alter

70 dedness-, and education-matched HCs, free of psychotropic medication for at least 12 weeks, viewed 60

71 All subjects had been free of psychotropic medication for at least 4 weeks.

72 The data supporting concomitant psychotropic medication for youths are almost exclusivel

73 dentify available information on concomitant psychotropic medication for youths.

74 Recent reports on the use of psychotropic medications for preschool-aged children wit

75 a clinical research facility completed by 75 psychotropic medication-free patients with remitted MDD

76 use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including

77 o the prevalence and patterns of concomitant psychotropic medication given to youths with emotional a

78 elements of detailed first-episode-specific psychotropic medication guidelines and a computerized de

79 Although mortality related to psychotropic medications has received much attention in

80 re widely prescribed, but how new classes of psychotropic medications have affected prescribing patte

81 Many other psychotropic medications have been considered and used t

82 % reported that they had been treated with a psychotropic medication in the past 12 months.

83 harmacodynamics, and side-effect profiles of psychotropic medication in this population.

84 stimated 27.2% of HIV-positive patients took psychotropic medications in 1996.

85 e 1955 was conducted to determine the use of psychotropic medications in breast-feeding women.

86 No controlled studies on the safety of psychotropic medications in nursing mothers were found.

87 over widespread overmedication and misuse of psychotropic medications in US youth.

88 95% CI=0.59-0.90) declined while use of only psychotropic medication increased (44.1% and 57.4%; adju

89 ctual disability have behaviour problems and psychotropic medication is a commonly used management st

90 g disorder; in the case of anorexia nervosa, psychotropic medication is generally reserved for patien

91 When psychotropic medication is used during breast-feeding, i

92 Combining psychotropic medications is common for people diagnosed

93 Rapid discontinuation of some psychotropic medications is followed by discontinuation

94 Finally, the use of psychotropic medications is not unusual in personality d

95 Despite evidence of the increasing use of psychotropic medications, little is known about the broa

96 Numerous other psychotropic medications may be considered, alone or in

97 Treatment with psychotropic medications may contribute to obesity in wa

98 Many psychotropic medications must be considered when treatin

99 Oculomotor tests were administered to 18 psychotropic medication-naive, nondepressed patients wit

100 but few studies, that examine the effect of psychotropic medication on anxiety disorders in children

101 ignificant effect or ameliorative effects of psychotropic medications on abnormal structural and func

102 egarding the effects of prenatal exposure to psychotropic medications on fetal outcome.

103 linical studies have demonstrated effects of psychotropic medications on PPI.

104 er Lhx6 mRNA levels were not attributable to psychotropic medications or illness chronicity.

105 These differences were not attributable to psychotropic medications or other comorbid factors.

106 lth conditions with only psychotherapy, only psychotropic medication, or their combination; the mean

107 All subjects were free of alcohol, psychotropic medications, or drugs of abuse.

108 nary frequency or leaking (P = .006), use of psychotropic medication (P = .009), and denial of life a

109 health diagnoses (P = 0.019) and the use of psychotropic medications (P = 0.015) were significantly

110 ases in the use of and costs associated with psychotropic medications, particularly for youths with m

111 Psychotropic medication polypharmacy is common in psychi

112 There was an increase in the number of psychotropic medications prescribed across years; visits

113 In all 3 data sources, psychotropic medications prescribed for preschoolers inc

114 compared NAVIGATE and community care on the psychotropic medications prescribed, side effects experi

115 3 months, falls, fall-related fractures, and psychotropic medication prescriptions.

116 rences in falls, fall-related fractures, and psychotropic medication prescriptions.

117 n mental disorder diagnoses, prescription of psychotropic medications, provision of psychotherapy, or

118 c treatment lasted 6 months and consisted of psychotropic medication, psychoeducation, and brief supp

119 36 healthy control (HC) participants free of psychotropic medication recruited from several psychiatr

120 small case series for each of the different psychotropic medications serve as the basis for suggeste

121 Most of the evidence on other psychotropic medications such as antidepressants, mood s

122 Psychotropic medications target glycogen synthase kinase

123 % CI=0.48-0.90) as well as psychotherapy and psychotropic medication together (40.0% and 32.1%; adjus

124 )) locus (HTR2A), previously associated with psychotropic medication treatment outcome.

125 t a major issue is the potential confound of psychotropic medication upon experimental measures.

126 telligence quotient and after accounting for psychotropic medication usage and comorbid psychopatholo

127 This study examined patterns of psychotropic medication use after the Sept. 11, 2001, te

128 The association between psychotropic medication use and MI is probably a reflect

129 Depression and psychotropic medication use are potential risk indicator

130 y mental disorders during the 3 prior years, psychotropic medication use during the prior year, and i

131 ffects on decreasing behavioral symptoms and psychotropic medication use in dementia residents in lon

132 The patterns of psychotropic medication use in outpatient medical practi

133 Psychotropic medication use in the past 12 months.

134 isk of incident MI and evaluates the role of psychotropic medication use in this relationship.

135 episode, dysphoria (2 weeks of sadness), and psychotropic medication use were assessed in 1981, and s

136 mine the association of mental disorders and psychotropic medication use with osteoporotic fracture r

137 for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item

138 over time by provider specialty, concomitant psychotropic medication use, number of annual visits, an

139 ore rapidly and has coincided with increased psychotropic medication use.

140 Outpatient mental health treatment and psychotropic-medication use in children and adolescents

141 Diagnostic Interview and a questionnaire on psychotropic medications used during the previous 6 mont

142 Psychotropic medication visits increased at comparable r

143 The number of visits during which a psychotropic medication was prescribed increased from 32

144 When data from patients taking psychotropic medication were excluded from the analysis,

145 nd adjusted costs for services and dispensed psychotropic medications were calculated.

146 Psychotropic medications were discontinued before random

147 6 months, and who were free of hormonal and psychotropic medications were recruited into 4 study gro

148 ntly face the need to decide whether to take psychotropic medications while breast-feeding.

149 ortion of mental health outpatients received psychotropic medication without psychotherapy.

150 essant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1